Skip to main content

Table 2 Cox proportional hazards model for disease recurrence

From: Prognostic value of metabolic activity of the psoas muscle evaluated by preoperative 18F-FDG PET-CT in breast cancer: a retrospective cross-sectional study

Covariate

Univariate analysis

Multivariate analysis

HR (95% CI)

P-value

HR (95% CI)

P-value

T stage

 T2

2.89 (1.030–8.106)

0.044

1.645 (0.548–4.935)

0.374

 T3

11.638 (3.801–35.633)

< 0.001

2.658 (0.551–12.819)

0.223

N stage

 N1

1.716 (0.639–4.608)

0.284

1.267 (0.413–3.889)

0.679

 N2

4.938 (1.521–16.037)

0.008

1.749 (0.318–9.631)

0.521

 N3

12.961 (4.582–36.666)

< 0.001

5.347 (1.162–24.603)

0.031

ER

0.206 (0.093–0.453)

< 0.001

0.873 (0.228–3.348)

0.843

PR

0.212 (0.092–0.487)

< 0.001

0.783 (0.194–3.163)

0.731

HER2

2.592 (1.190–5.643)

0.016

2.843 (0.743–10.872)

0.127

TNBC

2.963 (1.245–7.052)

0.014

4.505 (0.801–25.329)

0.088

Breast-conserving surgery

0.224 (0.102–0.495)

< 0.001

0.502 (0.187–1.352)

0.173

SUVRmean

3.633 (1.668–7.911)

0.001

2.007 (0.755–5.335)

0.163

SUVRmax

4.987 (2.167–11.475)

< 0.001

3.014 (1.002–9.071)

0.050

  1. ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, TNBC triple-negative breast cancer, SUVRmax, ratio of the maximum standard uptake value; SUVRmean, ratio of the mean standard uptake value